Episodes
Friday Feb 03, 2023
Friday Feb 03, 2023
Hyperkalemia is a common electrolyte disorder in patients with CKD that can be exacerbated by renin-angiotensin-aldosterone system (RAAS) inhibitors. While hyperkalemia poses potential risks to patients with CKD, the potentially negative impact of discontinuing RAAS inhibitor therapy on long-term renal and cardiovascular outcomes in CKD patients is unclear.
Guest Author: Michelle A. Fravel, PharmD, BCPS
Music by Good Talk
Thursday Oct 13, 2022
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
Thursday Oct 13, 2022
Thursday Oct 13, 2022
The 2022 AHA/ACC/HFSA Heart Failure Guidelines is a much-needed update and consolidates previously published recommendations. In the written commentary we describe the top ten things every clinician should know about the 2022 AHA/ACC/HFSA Heart Failure Guidelines. This podcast episode highlights some of the key recommendations from the guidelines and addresses some of the practical implications.
Guest Authors: Madison Yates, PharmD and Megan Supple, PharmD, BCACP, CPP
Music by Good Talk
Friday Jun 03, 2016
PATHWAY-2: Does the road lead to spironolactone for resistant hypertension?
Friday Jun 03, 2016
Friday Jun 03, 2016
Resistant hypertension (RH) is frequently encountered in primary care practice and often presents a significant clinical challenge because limited evidence-based guidance exists. RH is a major cause of cardiovascular disease and death, and has been associated with a 50% increased risk of myocardial infarction, stroke, congestive heart failure, and chronic kidney disease when compared to patients without RH. The American Heart Association defines RH as uncontrolled BP despite maximal treatment with a three-drug regimen, ideally including a diuretic. The exact prevalence of RH is unknown, but large randomized controlled trials suggest it affects one in five patients with elevated BP. Previous research findings suggest chlorthalidone, spironolactone, and eplerenone are all effective add-on therapies when BP remains uncontrolled with typical first line agents. The Pathway-2 study provides the first direct comparative evaluation of three different four-drug antihypertensive regimens.